|Bid||93.73 x 1800|
|Ask||93.72 x 800|
|Day's Range||93.36 - 93.81|
|52 Week Range||72.30 - 93.89|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||17.41|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||104.00|
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.
As it builds out high-profile biotech developments on the Peninsula, BioMed Realty is digging into the East Bay in a big way. The San Diego-based unit of Blackstone Group LP (NYSE: BX) paid about $135 million for the six-story, 250,000-square-foot structure, the company said Wednesday, which includes an adjacent space for as much as 850,000 square feet of additional lab and office space. "We plan to offer in excess of 1 million square feet of space to innovative tenants, including biotech and other laboratory users," Denis Sullivan, executive vice president and chief investment officer for BioMed, said in a statement.
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...
Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.
Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale. Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed". Francesco Balestrieri, head of Sandoz's Europe region, will become interim CEO to oversee what Narasimhan called "a multi-year transformation program" in which Sandoz re-focuses on biosimilars -- copies of patent-expired biological drugs made by rivals -- and hard-to-make generics like insulin.
The head of Novartis’s generic drugs business, Sandoz, has stepped down, sparking fresh speculation about its future. Vas Narasimhan, chief executive of the Swiss drugmaker, said that Richard Francis, who has run Sandoz for the past five years, had “decided that for personal reasons he cannot commit to stay with Sandoz” for the duration of “a multiyear transformation programme”. Mr Francis’ departure will revive speculation that Mr Narasimhan, who has sought to focus the company on its higher margin innovative medicines business since taking charge last year, is eyeing a potential spin-off of Sandoz.
The chief compliance officer, once responsible for simply making sure companies stayed within legal bounds, is now responsible for a broader range of priorities. Among them: guarding a company’s reputation, ensuring investors and government agencies have the information they need, and strengthening internal culture around compliance efforts, executives said Tuesday during a panel discussion hosted by Dow Jones Risk & Compliance and The Wall Street Journal.
Celgene and Novartis could go head-to-head in a patent battle over multiple sclerosis treatment ozanimod, an analyst said Tuesday. Novartis has a key patent for the S1P modulator drug class.
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.
How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Business transformation Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company. According to the company’s
In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate, an intravenous treatment for certain types of cancer. Drug firm Novartis, which in 2018 acquired rights to sell it in Europe, is asking more than five times that for its proprietary version, Lutathera. Thomasa is part of a protest against high drug prices launched by an unlikely group of rebels: Dutch pharmacies.